Combined Application of Photofrin II and Ionizing Radiation in an in vitro and in vivo Experiment

2012 ◽  
Vol 25 (01) ◽  
Author(s):  
M Shaffer ◽  
A Hofstetter
2020 ◽  
Vol 39 (5) ◽  
pp. 477-490
Author(s):  
Attalla Farag El-kott ◽  
Ali S. Alshehri ◽  
Heba S. Khalifa ◽  
Abd-El-karim M. Abd-Lateif ◽  
Mohammad Ali Alshehri ◽  
...  

This study investigated whether the mechanism underlying the neurotoxic effects of cadmium chloride (CdCl2) in rats involves p66Shc. This study comprised an initial in vivo experiment followed by an in vitro experiment. For the in vivo experiment, male rats were orally administered saline (vehicle) or CdCl2 (0.05 mg/kg) for 30 days. Thereafter, spatial and retention memory of rats were tested and their hippocampi were used for biochemical and molecular analyses. For the in vitro experiment, control or p66Shc-deficient hippocampal cells were treated with CdCl2 (25 µM) in the presence or absence of SP600125, a c-Jun N-terminal kinase (JNK) inhibitor. Cadmium chloride impaired the spatial learning and retention memory of rats; depleted levels of glutathione and manganese superoxide dismutase; increased reactive oxygen species (ROS), tumor necrosis factor α, and interleukin 6; and induced nuclear factor kappa B activation. Cadmium chloride also decreased the number of pyramidal cells in the CA1 region and induced severe damage to the mitochondria and endoplasmic reticulum of cells in the hippocampi of rats. Moreover, CdCl2 increased the total unphosphorylated p66Shc, phosphorylated (Ser36) p66Shc, phosphorylated JNK, nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, cytochrome c, and cleaved caspase-3. A dose–response increase in cell death, ROS, DNA damage, p66Shc, and NADPH oxidase was also observed in cultured hippocampal cells treated with CdCl2. Of note, all of these biochemical changes were attenuated by silencing p66Shc or inhibiting JNK with SP600125. In conclusion, CdCl2 induces hippocampal ROS generation and apoptosis by promoting the JNK-mediated activation of p66Shc.


2018 ◽  
Vol 59 (6) ◽  
pp. 509-522 ◽  
Author(s):  
Jian Zhang ◽  
Xinyu Qiu ◽  
Kedi Xi ◽  
Wentao Hu ◽  
Hailong Pei ◽  
...  

1986 ◽  
Vol 6 (2) ◽  
pp. 131-136 ◽  
Author(s):  
J. Stuart Nelson ◽  
Chung-Ho C. Sun ◽  
Michael W. Berns
Keyword(s):  

2010 ◽  
Vol 55 (2) ◽  
pp. 713-721 ◽  
Author(s):  
Tatiana Küster ◽  
Britta Stadelmann ◽  
Corina Hermann ◽  
Sabrina Scholl ◽  
Jennifer Keiser ◽  
...  

ABSTRACTAlveolar echinococcosis (AE) is caused by the metacestode stage of the fox tapewormEchinococcus multilocularisand causes severe disease in the human liver, and occasionally in other organs, that is fatal when treatment is unsuccessful. The present chemotherapy against AE is based on mebendazole and albendazole. Albendazole treatment has been found to be ineffective in some instances, is parasitostatic rather than parasiticidal, and usually involves the lifelong uptake of large doses of drugs. Thus, new treatment options are urgently needed. In this study we investigated thein vitroandin vivoefficacy of mefloquine againstE. multilocularismetacestodes. Treatment using mefloquine (20 μM) againstin vitrocultures of metacestodes resulted in rapid and complete detachment of large parts of the germinal layer from the inner surface of the laminated layer within a few hours. Thein vitroactivity of mefloquine was dependent on the dosage.In vitroculture of metacestodes in the presence of 24 μM mefloquine for a period of 10 days was parasiticidal, as determined by murine bioassays, while treatment with 12 μM was not. Oral application of mefloquine (25 mg/kg of body weight administered twice a week for a period of 8 weeks) inE. multilocularis-infected mice was ineffective in achieving any reduction of parasite weight, whereas treatment with albendazole (200 mg/kg/day) was highly effective. However, when the same mefloquine dosage was applied intraperitoneally, the reduction in parasite weight was similar to the reduction seen with oral albendazole application. Combined application of both drugs did not increase the treatment efficacy. In conclusion, mefloquine represents an interesting drug candidate for the treatment of AE, and these results should be followed up in appropriatein vivostudies.


2007 ◽  
Vol 11 (10) ◽  
pp. 736-741 ◽  
Author(s):  
Pamela Schaffer ◽  
Ulrike Kulka ◽  
Birgit Ertl-Wagner ◽  
Roswita Hell ◽  
Alina Balandin ◽  
...  

Several clinical studies, as well as investigations performed on tissue cultures and murine tumor models, have demonstrated the in vitro and in vivo efficacy of Photofrin II and hypericin as radiosensitizing agents. The mechanisms involved in the radiosensitizing action of Photofrin II and hypericin are partially understood; the recognition of the major role performed by oxygen regarding the modulation of cellular radiosensitivity has prompted the present investigations on the relevance of oxygenation for the success of Photofrin II or hypericin-based radiation therapy of tumors. RT4 human bladder carcinoma cell lines were seeded and incubated with various concentrations of Photofrin II or hypericin under ambient and 5% oxygen levels. The cells were irradiated with ionizing radiation between 1 and 6 Gy. The same experiments were repeated with Photofrin II and hypericin alone, without radiation. The cell survival was evaluated. The results demonstrated an increase of radiation-induced cell damage in the presence of Photofrin II and hypericin, respectively, when sufficient oxygen was available. Low levels of oxygen reduced the activity of Photofrin II as well as of hypericin as a radiosensitizer, with minimal tumor damage ( p < 0.05 in a Student t-test). The mechanism of action of Photofrin II and hypericin as radiosensitizers requires the presence of sufficiently high oxygen concentrations.


Sign in / Sign up

Export Citation Format

Share Document